CytoSorbents, Inc. Recognized as "Company Most Likely to Succeed" at the 2009 New Jersey Venture Conference and

MONMOUTH JUNCTION, NJ, Mar 30 (MARKET WIRE) --
CytoSorbents, Inc., the wholly-owned operating subsidiary of MedaSorb
Technologies Corporation (OTCBB: MSBT), announced it was chosen as
"Company Most Likely to Succeed" by independent judges at the 2009 New
Jersey Technology Council Venture Conference on March 27, 2009. The
Company was one of 60 healthcare and technology companies presenting at
the conference who were eligible for this coveted all-around award. "We
feel extremely honored to have received this award, particularly against
such solid competition," stated Dr. Phillip Chan, CEO. "It is especially
gratifying that others recognize the significant value we are building
and the potential of our technology to treat severe sepsis, one of the
top medical causes of death in the world. We are committed to increasing
shareholder value by making significant progress on key milestones and
objectives, including our European Sepsis Trial. Among other means, we
will continue to foster increased awareness of our Company through venues
such as the New Jersey Technology Council Venture Conference and the In3
West Conference that we presented at in early March. Our story has been
getting stronger and has been well-received because it is based on
compelling science and our unique CytoSorb(TM) blood purification
technology."

CytoSorbents provides the following clinical update on its current
European Sepsis Trial:

-- Twenty-two patients have been enrolled to date from three trial sites.
-- Recruitment is now expected to accelerate with a current total of ten
initiated clinical sites.
-- The CytoSorb(TM) treatment has been well-tolerated by patients and
easily administered by hospital staff on standard dialysis equipment.
-- There have been no serious device related adverse events associated
with CytoSorb(TM) treatment in more than 450 human treatments,
approximately 90 of which have been in septic patients.
-- The Company continues to expect trial completion in 2009 with the goal
of CE Mark approval and initial commercial sales in Europe next year.

The Company is currently upgrading its websites (www.medasorb.com and
www.cytosorbents.com) and plans to have updated investor materials
available for download in the near future. These materials are available
now by email request at info@medasorb.com

About MedaSorb, CytoSorbents and CytoSorb(TM)

MedaSorb Technologies Corporation, with its wholly-owned operating
subsidiary, CytoSorbents, Inc., is a medical device company focused on the
treatment of severe sepsis with its proprietary CytoSorb(TM) resin. Severe
sepsis afflicts an estimated 18 million people worldwide each year,
killing one in every three patients, despite the best medical treatment.
CytoSorb(TM) is designed to treat sepsis by broadly reducing cytokines and
toxins from blood that can cause organ failure and potentially death.
After a patient's blood is pumped through a CytoSorb(TM) cartridge,
cytokines and toxins are adsorbed and removed by the resin. Treated blood
is then returned to the patient. The Company is currently evaluating
CytoSorb(TM) in its randomized, controlled, open-label European Sepsis
Trial in up to 80 patients with severe sepsis and respiratory failure.
MedaSorb has also developed a number of different resins using its
platform technology. These were designed for a variety of potential
healthcare applications including, for example, improved hemodialysis,
cytokine removal in inflammatory disorders, and drug removal or
detoxification.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify
for the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially
from those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon
any such forward-looking statements. Actual results may differ materially
from those expressed or implied by the statements herein. MedaSorb
Technologies Corporation believes that its primary risk factors include,
but are not limited to: obtaining government approvals including required
FDA approvals; ability to successfully develop commercial operations;
dependence on key personnel; acceptance of the Company's medical devices
in the marketplace; the outcome of pending and potential litigation;
compliance with governmental regulations; reliance on research and testing
facilities of various universities and institutions; the ability to obtain
adequate financing in the future when needed; product liability risks;
limited manufacturing experience; limited marketing, sales and
distribution experience; market acceptance of the Company's products;
competition; unexpected changes in technologies and technological
advances; and other factors detailed in the Company's Form 10-KSB filed
with the SEC on April 15, 2008, which is available at http://www.sec.gov.

Contact:
MedaSorb Technologies Corporation
David Lamadrid
(732) 329-8885 ext. 816
DavidL@medasorb.com

Copyright 2009, Market Wire, All rights reserved.

-0-